Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Meihua Wang(University of Electronic Science and Technology of China), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chen Hu(Central South University), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cong Chen(Fujian University of Traditional Chinese Medicine), Xiaoyun Li(Nanjing University), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas Jemielita(Merck & Co., Inc., Rahway, NJ, USA (United States))
Journal for ImmunoTherapy of Cancer
February 8, 2019
10.1186/s40425-019-0513-4
Cited by 25

Related Papers

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
|Science|2018|2.3k